Rechallenge of EGFR inhibitors in the treatment of metastatic colorectal cancer - case report

01/2020

MUDr. Hana Korunková

Radioterapeutické a onkologické oddělení, FN Plzeň

SUMMARY

A case of a patient who has been treated for metastatic colorectal cancer for six years will be presented. Patient was treated with six lines of systemic treatment and two local liver treatments. All available cytostatics indicated for the diagnosis except for capecitabine, targeted therapies except bevacizumab were used in systemic treatment, and the rechallenge of the EGFR inhibitor was used.

Key words

metastatic colorectal cancer, epidermal growth factor receptor inhibitor, EGFR, vascular endothelial growth factor receptor inhibitor, VEGFR